Tracon Pharmaceuticals Stock News

TRACON Pharmaceuticals (NASDAQ:TCON) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations. Analyst Ratings This is a breakdown of recent recommendations and price targets for TRACON Pharmaceuticals []

Insider sales are generally a sign the market is about to drop, but not everyone's selling. Here are five companies with insider buying.

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer

TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q3 2021 Results - Earnings Call Transcript

TRACON Pharmaceuticals (NASDAQ:TCON) Inc said it has ended its third quarter 2021 with cash and equivalents of $29.9 million as of September 30, 2021, as the company expects to file an investigation

SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer

TRACON Pharmaceuticals has bolstered its board with the appointment of Carol Lam, who was previously senior vice-president and deputy general counsel at chip giant Qualcomm, as a new director. Lam was

SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therape

TRACON Pharmaceuticals Inc. has entered into a collaborative partnership agreement with China-based Eucure Biopharma for the development of CTLA-4 antibody YH001 in multiple oncology indications, incl

YH001 is a potential best-in-class CTLA-4 antibody with enhanced ADCC and CDC effector functions

SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cance

SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cance

Sarcoma is not one of the many cancers that reaches top billing in the discussion of cancer research.  The cancer starts in tissues like bone, muscle or soft tissue and affects a relatively small, 12

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cance

Clinical-stage pipeline includes envafolimab to treat soft-tissue sarcoma Awarded Orphan Drug designation for TRC102 to treat brain and spinal cord cancers Looking for partnerships to help with regul